(Q36861592)

16 August 2017

1 reference

title

Broadening the clinical use of platinum drug-based chemotherapy with new analogues. Satraplatin and picoplatin (English)

1 reference

16 August 2017

1 reference

1 reference

1 reference

Lloyd Kelland

1

1 reference

16 August 2017

language of work or name

English

0 references

publication date

1 July 2007

1 reference

Expert Opinion on Investigational Drugs

16 August 2017

published in

1 reference

16 August 2017

volume

16

1 reference

16 August 2017

issue

7

1 reference

16 August 2017

page(s)

1009-1021

1 reference

Chemotherapy for ovarian cancer--a consensus statement on standard practice.

16 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.7.1009

New platinum antitumor complexes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.7.1009

Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.7.1009

A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.7.1009

In vitro circumvention of cisplatin resistance by the novel sterically hindered platinum complex AMD473

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.7.1009

Lack of nephrotoxicity of oral ammine/amine platinum (IV) dicarboxylate complexes in rodents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.7.1009

An update on satraplatin: the first orally available platinum anticancer drug

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.7.1009

Biotransformation of the platinum drug JM216 following oral administration to cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.7.1009

Intracellular metabolism of the orally active platinum drug JM216: influence of glutathione levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.7.1009

Potent and non-specific inhibition of cytochrome P450 by JM216, a new oral platinum agent.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.7.1009

Satraplatin activation by haemoglobin, cytochrome C and liver microsomes in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.7.1009

Modulation of the cellular pharmacology of JM118, the major metabolite of satraplatin, by copper influx and efflux transporters

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.7.1009

Gene-specific repair of Pt/DNA lesions and induction of apoptosis by the oral platinum drug JM216 in three human ovarian carcinoma cell lines sensitive and resistant to cisplatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.7.1009

Novel mechanisms of platinum drug resistance identified in cells selected for resistance to JM118 the active metabolite of satraplatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.7.1009

Phase I clinical and pharmacokinetic study of the oral platinum analogue JM216 given daily for 14 days.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.7.1009

Phase II study of oral platinum drug JM216 as first-line treatment in patients with small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.7.1009

A phase II trial of JM-216 in cervical cancer: an NCIC CTG study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.7.1009

Phase I study of JM-216 (an oral platinum analogue) in combination with paclitaxel in patients with advanced malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.7.1009

Combined effects of the orally active cisplatin analog, JM216, and radiation in antitumor therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.7.1009

Satraplatin: an orally available platinum analog for the treatment of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.7.1009

A phase I trial of the oral platinum analogue JM216 with concomitant radiotherapy in advanced malignancies of the chest

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.7.1009

Phase II study of oral bis (aceto) ammine dichloro (cyclohexamine) platinum (IV) (JM-216, BMS-182751) given daily x 5 in hormone refractory prostate cancer (HRPC).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.7.1009

Phase III trial of satraplatin, an oral platinum plus prednisone vs. prednisone alone in patients with hormone-refractory prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.7.1009

Non-cross resistance of ZD0473 in acquired cisplatin-resistant lung cancer cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.7.1009

Lack of a role for MRP1 in platinum drug resistance in human ovarian cancer cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.7.1009

Retention of activity by the new generation platinum agent AMD0473 in four human tumour cell lines possessing acquired resistance to oxaliplatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.7.1009

Genomic imbalances associated with acquired resistance to platinum analogues

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.7.1009

Sequence-dependent synergism between the new generation platinum agent ZD0473 and paclitaxel in cisplatin-sensitive and -resistant human ovarian carcinoma cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.7.1009

In vitro effects of combinations of cis-amminedichloro (2-methylpyridine) platinum (II) (ZD0473) with other novel anticancer drugs on the growth of SBC-3, a human small cell lung cancer cell line

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.7.1009

Antiproliferative effects of ZD0473 (AMD473) in combination with 5-fluorouracil or SN38 in human colorectal cancer cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.7.1009

A Phase I clinical and pharmacological study of cis-diamminedichloro(2-methylpyridine) platinum II (AMD473).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.7.1009

ZD0473 treatment in lung cancer: an overview of the clinical trial results

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.7.1009

A phase II trial of ZD0473 in platinum-pretreated ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.7.1009

Phase II trial of ZD0473 as second-line therapy in mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.7.1009

A phase II study of ZD0473 given as a short infusion every 3 weeks to patients with advanced or metastatic breast cancer: a National Cancer Institute of Canada Clinical Trials Group trial, IND 129.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.7.1009

A phase I study of ZD0473 combined with paclitaxel for the treatment of solid malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.7.1009

A phase I, dose escalation trial of ZD0473, a novel platinum analogue, in combination with gemcitabine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.7.1009

A phase I study of AMD473 and docetaxel given once every 3 weeks in patients with advanced refractory cancer: a National Cancer Institute of Canada-Clinical Trials Group trial, IND 131.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.7.1009

ZD0473 combined with other chemotherapeutic agents for the treatment of solid malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.7.1009

New-generation platinum drugs in the treatment of cisplatin-resistant cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.7.1009

A Phase 2 trial of the liposomal DACH platinum L-NDDP in patients with therapy-refractory advanced colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.7.1009

Intraperitoneal cisplatin and paclitaxel in ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.7.1009

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.7.1009

The mTOR inhibitor RAD001 sensitizes tumor cells to DNA-damaged induced apoptosis through inhibition of p21 translation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.7.1009

10.1517/13543784.16.7.1009

21 January 2018

Identifiers

DOI

1 reference

16 August 2017

1 reference